Couñago, F. (Felipe)

Filtering

2018 - 20203

Settings

Author search.filters.isAuthorOfPublication.a0686d11-6417-431e-8266-5f43824c0490

Search Results

Now showing 1 - 3 of 3
  • Thumbnail Image
    Lung cancer screening, what has changed after the latest evidence?
    (Baishideng Publishing Group Inc, 2020) Seijo, L. (Luis); Couñago, F. (Felipe); Trujillo-Reyes, J. (Juan Carlos); Martínez-Tellez, E. (Elisabeth)
    Lung cancer (LC) is still one of the most frequent cancers with a high related mortality. Their prognosis is directly proportional to the stage at the time of diagnosis. Seventy percent are currently diagnosed in advanced or locally advanced stage (higher than stage III), making a cure unlikely for the majority of patients. Developments in LC treatment are significant however they do not seem to be enough to reverse the current situation, at least, in a short period of time. Despite recent advances in treatment, primary prevention and early diagnosis appear to be the key to reduce the incidence and mortality of this disease. Many countries have developed LC screening programs based on the results of clinical trials published in recent years. The aim of this paper is to review the latest results of the NEderlands Leuvens Longkanker Screenings Onderzoek and compare them with the findings of the National Lung Screening Trial. We address the question whether it is necessary to continue discussing the evidence regarding LC screening. In both trials, there is a clear impact on LC mortality but, with a modest reduction in over all mortality. Undoubtedly, the benefit of screening can be expected to grow as low-dose computed tomographys are performed over longer periods of time.
  • Thumbnail Image
    Immunotherapy moves to the early-stage setting in non-small cell lung cancer: emerging evidence and the role of biomarkers
    (MDPI AG, 2018) Berraondo, P. (Pedro); Couñago, F. (Felipe); Hernando-Trancho, F. (Florentino); Calvo, V. (Virginia); Mielgo-Rubio, X. (Xabier); Conde, E. (Esther); Martín, M. (Margarita); De-Castro, J. (Javier); López-Ríos, F. (Fernando); Provencio, M. (Mariano); Luna, J. (Javier); Remon, J. (Jordi); Higuera, O. (Oliver); Jarabo, J.R. (José Ramón)
    Despite numerous advances in targeted therapy and immunotherapy in the last decade, lung cancer continues to present the highest mortality rate of all cancers. Targeted therapy based on specific genomic alterations, together with PD-1 and CTLA-4 axis blocking-based immunotherapy, have significantly improved survival in advanced non-small cell lung cancer (NSCLC) and both therapies are now well-established in this clinical setting. However, it is time for immunotherapy to be applied in patients with early-stage disease, which would be an important qualitative leap in the treatment of lung cancer patients with curative intent. Preliminary data from a multitude of studies are highly promising, but therapeutic decision-making should be guided by an understanding of the molecular features of the tumour and host. In the present review, we discuss the most recently published studies and ongoing clinical trials, controversies, future challenges and the role of biomarkers in the selection of best therapeutic options.
  • Thumbnail Image
    GOECP/SEOR clinical recommendations for lung cancer radiotherapy during the COVID-19 pandemic
    (Baishideng, 2020) García, R. (Rafael); Couñago, F. (Felipe); Gómez-Caamaño, A. (Antonio); Rodríguez, A. (Aurora); Rodríguez-de-Dios, N. (Nuria); Casas, F. (Francesc); Serrano-Andreu, J. (Javier); Luna, J. (Javier); Navarro-Martin, A. (Arturo); Contreras, J. (Jorge)
    The coronavirus disease 2019 crisis has had a major and highly complex impact on the clinical practice of radiation oncology worldwide. Spain is one of the countries hardest hit by the virus, with devastating consequences. There is an urgent need to share experiences and offer guidance on decision-making with regard to the indications and standards for radiation therapy in the treatment of lung cancer. In the present article, the Oncological Group for the Study of Lung Cancer of the Spanish Society of Radiation Oncology reviews the literature and establishes a series of consensus-based recommendations for the treatment of patients with lung cancer in different clinical scenarios during the present pandemic.